Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 360

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry

Open access
Gautschi, Oliver, Milia, Julie, Filleron, Thomas, Wolf, Juergen, Carbone, David P., Owen, Dwight, Camidge, Ross, Narayanan, Vignhesh, Doebele, Robert C., Besse, Benjamin, Remon-Masip, Jordi, Janne, Pasi A., Awad, Mark M., Peled, Nir, Byoung, Chul-Cho, Karp, Daniel D., Van Den Heuvel, Michael, Wakelee, Heather A., Neal, Joel W., Mok, Tony S.K., Yang, James C.H., Ou, Sai-Hong Ignatius, Pall, Georg, Froesch, Patrizia, Zalcman, Gérard, Gandara, David R., Riess, Jonathan W., Velcheti, Vamsidhar, Zeidler, Kristin, Diebold, Joachim, Früh, Martin, Michels, Sebastian, Monnet, Isabelle, Popat, Sanjay, Rosell, Rafael, Karachaliou, Niki, Rothschild, Sacha I., Shih, Jin-Yuan, Warth, Arne, Muley, Thomas, Cabillic, Florian, Mazières, Julien, Drilon, Alexander·2017·Journal of Clinical Oncology

Abstract

Purpose: In addition to prospective trials for non–small-cell lung cancers (NSCLCs) that are driven by less common genomic alterations, registries provide complementary information on patient response to targeted therapies. Here, we present the results of an international registry of patients with RET-rearranged NSCLCs, providing the largest data set, to our knowledge, on outcomes of RET-directed therapy thus far. Methods: A global, multicenter network of thoracic oncologists identified patients with pathologically confirmed NSCLC that harbored a RET rearrangement. Molecular profiling was performed locally by reverse transcriptase polymerase chain reaction, fluorescence in situ hybridization, or next-generation sequencing. Anonymized data—clinical, pathologic, and molecular features—were collected centrally and analyzed by an independent statistician. Best response to RET tyrosine kinase inhibition administered outside of a clinical trial was determined by RECIST v1.1. Results: By April 2016, 165 patients with RET-rearranged NSCLC from 29 centers across Europe, Asia, and the United States were accrued. Median age was 61 years (range, 29 to 89 years). The majority of patients were never smokers (63%) with lung adenocarcinomas (98%) and advanced disease (91%). The most frequent rearrangement was KIF5B-RET (72%). Of those patients, 53 received one or more RET tyrosine kinase inhibitors in sequence: cabozantinib (21 patients), vandetanib (11 patients), sunitinib (10 patients), sorafenib (two patients), alectinib (two patients), lenvatinib (two patients), nintedanib (two patients), ponatinib (two patients), and regorafenib (one patient). The rate of any complete or partial response to cabozantinib, vandetanib, and sunitinib was 37%, 18%, and 22%, respectively. Further responses were observed with lenvantinib and nintedanib. Median progression-free survival was 2.3 months (95% CI, 1.6 to 5.0 months), and median overall survival was 6.8 months (95% CI, 3.9 to 14.3 months). Conclusion: Available multikinase inhibitors had limited activity in patients with RET-rearranged NSCLC in this retrospective study. Further investigation of the biology of RET-rearranged lung cancers and identification of new targeted therapeutics will be required to improve outcomes for these patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2016.70.9352

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 41 references

Cited by

See all 360

Metadata

Authors
Gautschi, O., Milia, J., Filleron, T., Wolf, J., Carbone, D. P., Owen, D., Camidge, R., Narayanan, V., Doebele, R. C., Besse, B., Remon-Masip, J., Janne, P. A., Awad, M. M., Peled, N., Byoung, C.-C., Karp, D. D., Van Den Heuvel, M., Wakelee, H. A., Neal, J. W., Mok, T. S. K., Yang, J. C. H., Ou, S.-H. I., Pall, G., Froesch, P., Zalcman, G., Gandara, D. R., Riess, J. W., Velcheti, V., Zeidler, K., Diebold, J., Früh, M., Michels, S., Monnet, I., Popat, S., Rosell, R., Karachaliou, N., Rothschild, S. I., Shih, J.-Y., Warth, A., Muley, T., Cabillic, F., Mazières, J., & Drilon, A.
Venue
Journal of Clinical Oncology
Published
2017-05-01
Volume
35
Issue
13
Pages
1403-1410
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2600348349
Cited by
360
References
41
FWCI
33.41
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. https://app.cochat.ai/papers/10.1200/jco.2016.70.9352
The paper
Gautschi, O., Milia, J., Filleron, T., Wolf, J., Carbone, D. P., Owen, D., Camidge, R., Narayanan, V., Doebele, R. C., Besse, B., Remon-Masip, J., Janne, P. A., Awad, M. M., Peled, N., Byoung, C.-C., Karp, D. D., Van Den Heuvel, M., Wakelee, H. A., Neal, J. W., . . . Drilon, A. (2017). Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2016.70.9352

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.